ISPOR 18th ANNUAL EUROPEAN CONGRESS AWARDS WINNERS

The ISPOR Research Presentation Podium and Poster Awards were established in 1998 to recognize the scientific merit of podium and poster presentations of the ISPOR Annual International Meetings, Annual European Congresses, Asia-Pacific and Latin America Conferences.

This year, the ISPOR judges evaluated podium presentations and nominated poster presentations. All podium presentations are considered for an award. Poster presentations in the top 20%, based on abstract review score, are considered and eligible for a poster presentation award.
Evaluations of scientific merit were based upon the following criteria:

  • Background provides appropriate perspective / context for the subject
  • Objectives / research questions are clearly stated
  • Research design / methods / modeling is appropriate and transparent (scores on this will determine winners in case of ties)
  • Data sources and/or sampling procedures are clear and appropriate
  • Data analyses are appropriate
  • Research objectives are met/addressed
  • Implications of findings are discussed
  • Factual information is kept separate from interpretations or implications
  • Abstract is presented in an unbiased manner
  • Clarity of presentation

THE RECIPIENTS  ARE: . . .

ISPOR Best Podium Research Presentation Awards

Best General Podium Presentations

CA1 - ANALYSIS OF THE RELATIONSHIP BETWEEN PATIENT-REPORTED OUTCOMES (PROS) AND CLINICAL OUTCOMES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS WITHOUT PRIOR CHEMOTHERAPY
Traina S1Li T1, Johnson K1, Ho KF2, Molina A3, Cella D4
1Janssen Research & Development, Raritan, NJ, USA, 2STAT-TU Inc., Toronto, ON, Canada, 3Janssen Research & Development, Menlo Park, CA, USA, 4Northwestern University Feinberg School of Medicine, Chicago, IL, USA

EA2 - ACCESS TO INNOVATIVE DRUGS IN PATIENTS WITH METASTATIC LUNG CANCER IN FRENCH PUBLIC HOSPITALS (THE TERRITOIRE STUDY)
Scherpereel A1, Fernandes J2, Cotté F3, Blein C4, Debieuvre D5Durand-Zaleski I6, Gaudin A3, Ozan N3, Saitta B4, Souquet P7, Vainchtock A4, Westeel V8, Chouaïd C9
1CHU Lille, Lille, France, 2Oc Santé, Montpellier, France, 3Bristol-Myers Squibb, Rueil-Malmaison, France, 4HEVA, Lyon, France,5Mulhouse Hospital, Mulhouse, France, 6URC Eco, Paris, France, 7Hospices Civils de Lyon, Lyon, France, 8Besançon Hospital, Besançon, France, 9CHIC, Créteil, France

 

PR2 - PREDICTING POST-AMNOG REBATE OUTCOMES FOR ONCOLOGY DRUGS
Subramanian D, Lazaro V
Qlaar Pte. Ltd., Singapore, Singapore


Best Student Podium Research Presentations

 

PR1 - DETERMINANTS OF ORPHAN DRUG PRICES IN FRANCE: REGRESSION ANALYSIS
Korchagina D1, Vataire A2, Toumi M3, Falissard B4, Aballéa S2
1University of Paris-Sud, Paris, France, 2Creativ-Ceutical, Paris, France, 3Aix-Marseille University, Marseille, France, 4Maison de Solenn, Paris, France

 

EA4 - ORPHAN DESIGNATIONS AND APPROVALS IN THE EU, UNITED STATES AND JAPAN
Korchagina D1, Tomita N2, Falissard B3, Toumi M4, Tavella F5
1University of Paris-Sud, Paris, France, 2National Institute of Public Health, Saitama, Japan, 3Maison de Solenn, Paris, France,4Aix-Marseille University, Marseille, France, 5Creativ-Ceutical, London, UK

RM8 - COMPARISON OF TIMED AUTOMATA WITH DISCRETE EVENT SIMULATION FOR MODELING PERSONALIZED TREATMENT DECISIONS: THE CASE OF METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Degeling K, Koffijberg H, Schivo S, Langerak R, IJzerman MJ
University of Twente, Enschede, The Netherlands

Best New Investigator Podium Research Presentations

 

VA3 - ECONOMIC EVALUATION OF CHILDREN VACCINATION FROM 2 TO 18 YEARS OF AGE WITH THE LIVE ATTENUATED INFLUENZA VACCINE COMPARED WITH THE EXISTING VACCINES IN THE PORTUGUESE SETTING
Ferreira J1, Trindade R1, Norte J1, Sackeyfio A2
1Astrazeneca Produtos Farmacêuticos Lda., Lisboa, Portugal, 2AstraZeneca Alderley House, Alderley Park, UK

MD4 - COST-EFFECTIVENESS OF 18F-FDG PET/CT FOR SCREENING DISTANT METASTASIS IN STAGE II/III BREAST CANCER PATIENTS OF THE UK, THE UNITED STATES AND THE NETHERLANDS
Miquel-Cases A1, Teixeira S1, Retèl V1, Steuten L2, Valdés Olmos R1, Rutgers E1, van Harten WH1
1Netherlands Cancer Institute, Amsterdam, The Netherlands, 2University of Washington and Panaxea bv, Seattle, WA, USA

CA3 - THE BURDEN OF CANCER IN EMERGING ECONOMIES: PRODUCTIVITY LOSS AS AN ALTERNATIVE PERSPECTIVE
Pearce A1, Hanly P2, Sharp L3, Soerjomataram I4
1National Cancer Registry Ireland, Cork, Ireland, 2National College of Ireland, Dublin, Ireland, 3Newcastle University, Newcastle, UK, 4International Agency for Research on Cancer, Lyon, France


ISPOR Best Poster Research Presentation Awards

Best General Poster Research Presentations

PCV71 - RESOURCE UTILISATION AND COSTS IN PATIENTS WITH POST-STROKE SPASTICITY IN THE UNITED KINGDOM
Raluy-Callado M1, Cox A1, MacLachlan S1, Gabriel S2Dinet J2
1Evidera, London, UK, 2IPSEN Pharma, Boulogne-Billancourt, France

 

PCV50 - COMPARATIVE EFFECTIVENESS ON CARDIOVASCULAR OUTCOMES OF METFORMIN INITIAL THERAPY AND ADD-ON SECOND-LINE DRUGS AMONG PATIENTS WITH TYPE 2 DIABETES
Kim Y1, Ko M1, Jo A1, Kang S1, Tchoe H1, Park C2, Kim H1, Choi J1, Park D3, Lee W3
1National Evidence based Health-care Collaborating Agency, Seoul, South Korea, 2National Evidence-based Health-care Collaborating Agency, Seoul, South Korea, 3Asan Medical Center, Seoul, South Korea

PRM137 - SCORING AND RESPONSIVENESS OF THE SELF-ASSESSMENT OF TREATMENT VERSION II QUESTIONNAIRE IN PATIENTS WITH PAINFUL DIABETIC PERIPHERAL NEUROPATHY
van Nooten FE1, Trundell D2, Staniewska D3, Revicki DA3
1Astellas Pharma BV, Leiden, The Netherlands, 2Evidera, Inc., London, UK, 3Evidera, Bethesda, MD, USA


Best Student Poster Research Presentations

PSY95 - THE RELATIONSHIP BETWEEN DISEASE SEVERITY AND QUALITY OF LIFE IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS
Geale K1, Henriksson M2, Schmitt-Egenolf M1
1Umeå University, Umeå, Sweden, 2Linköping University, Linköping, Sweden

PCV163 - ANGIOTENSIN CONVERTING ENZYME INHIBITORS PRESCRIBING PATTERN FOR DIFFERENT INDICATIONS: A POPULATION BASED STUDY
Mahmoudpour SH1, Asselbergs FW2, Souverein PC1, de Boer A1, Maitland-van der Zee A1
1Utrecht University, UTRECHT, The Netherlands, 2University Medical Centre Utrecht, UTRECHT, The Netherlands

PCN260 - BURDEN OF METASTATIC RENAL CELL CARCINOMA IN FRANCE FROM 2008 TO 2013: ANALYSIS OF THE FRENCH NATIONAL HOSPITAL DATABASE
Maroun R
1
, Maunoury F2, Benjamin L1, Nachbaur G1, Durand-Zaleski I3
1GSK France, Marly le roi, France, 2Statesia, Le Mans, France, 3URC Eco, Paris, France

Best New Investigator Poster Research Presentations

PDB79 - IMPACT OF A TELEPHONIC OUTREACH PROGRAM ON MEDICATION ADHERENCE IN MEDICARE ADVANTAGE PRESCRIPTION DRUG (MAPD) PLAN BENEFICIARIES
Park H, Adeyemi A, Roane T
University of Florida, Gainesville, FL, USA

PDB1 - RISK OF NEW-ONSET DIABETES ASSOCIATED WITH CONCOMITANT ANTIDEPRESSANT, INHALED CORTICOSTEROIDS, AND STATIN USE AMONG MEDICAID BENEFICIARIES WITH COPD
Ajmera MR
1
, Sambamoorthi U2
1RTI Health Solutions, RTP, NC, USA, 2West Virginia University, Morgantown, WV, USA

PUK11 - COST-CONSEQUENCES ANALYSIS OF FESOTERODINE AT FLEXIBLE-DOSE IN THE THERAPY OF OVERACTIVE BLADDER IN ROUTINE MEDICAL PRACTICE
Peral C1, Rejas J2, Ramos J1, Sanchez-Ballester F3, Garcia-Mediero JM4
1Pfizer S.L.U., Alcobendas (Madrid), Spain, 2Pfizer, Alcobendas, Spain, 3Department of Urology, Valencia, Spain, 4Hospital MD Anderson, Madrid, Spain

Economic evaluation of flexible-dose Fesoterodine, including two treatment groups, in the management of Overactive Bladder in routine clinical practice, from the Spanish NHS perspective.

ISPOR would like to thank all the judges who have volunteered their time and efforts during the meeting to score podium and poster research presentations.

 

Return to ISPOR Awards Index Page